EP2197433A4 - Regulating glp-1 and sglt-1 in gastrointestinal cells - Google Patents

Regulating glp-1 and sglt-1 in gastrointestinal cells

Info

Publication number
EP2197433A4
EP2197433A4 EP08798295A EP08798295A EP2197433A4 EP 2197433 A4 EP2197433 A4 EP 2197433A4 EP 08798295 A EP08798295 A EP 08798295A EP 08798295 A EP08798295 A EP 08798295A EP 2197433 A4 EP2197433 A4 EP 2197433A4
Authority
EP
European Patent Office
Prior art keywords
sglt
gastrointestinal cells
glp
regulating
regulating glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08798295A
Other languages
German (de)
French (fr)
Other versions
EP2197433A2 (en
Inventor
Robert F Margolskee
Soraya Shirazi-Beechey
Josephine Egan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of EP2197433A2 publication Critical patent/EP2197433A2/en
Publication of EP2197433A4 publication Critical patent/EP2197433A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP08798295A 2007-08-20 2008-08-20 Regulating glp-1 and sglt-1 in gastrointestinal cells Withdrawn EP2197433A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96546307P 2007-08-20 2007-08-20
PCT/US2008/073756 WO2009026389A2 (en) 2007-08-20 2008-08-20 Regulating glp-1 and sglt-1 in gastrointestinal cells

Publications (2)

Publication Number Publication Date
EP2197433A2 EP2197433A2 (en) 2010-06-23
EP2197433A4 true EP2197433A4 (en) 2010-09-08

Family

ID=40378983

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08798295A Withdrawn EP2197433A4 (en) 2007-08-20 2008-08-20 Regulating glp-1 and sglt-1 in gastrointestinal cells

Country Status (2)

Country Link
EP (1) EP2197433A4 (en)
WO (1) WO2009026389A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
DE102009027744A1 (en) 2009-07-15 2011-01-20 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Precursor compounds of sweet receptor antagonists for the prevention or treatment of diseases
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
JP5905187B2 (en) 2009-12-02 2016-04-20 国立大学法人 東京大学 Sweet receptor expression construct, cell body expressing the same, and use thereof
WO2012054528A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
JP2014505011A (en) * 2010-10-19 2014-02-27 エルセリクス セラピューティクス インコーポレイテッド Chemosensory receptor ligand based therapy
EA201370099A1 (en) 2010-10-19 2013-11-29 Элселикс Терапьютикс, Инк. THERAPY ON THE BASIS OF LIGANDS OF CHEMOSENSOR RECEPTORS
CN103402358A (en) * 2010-10-19 2013-11-20 埃尔舍利克斯治疗公司 Chemosensory receptor ligand-based therapies
GB201804816D0 (en) * 2018-03-26 2018-05-09 Anglia Ruskin Univ Higher Education Corporation Cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
KR20050089156A (en) * 2002-12-04 2005-09-07 깃세이 야쿠힌 고교 가부시키가이샤 Preventive or remedy for diseases caused by hyperglycemia
US20050244810A1 (en) * 2003-09-29 2005-11-03 Egan Josephine M Taste signaling in gastrointestinal cells
WO2005036971A1 (en) * 2003-10-16 2005-04-28 Techcom Group, Llc Reduced digestible carbohydrate food having reduced blood glucose response
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANI PATRICE D ET AL: "Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats", BRITISH JOURNAL OF NUTRITION, vol. 98, no. 1, July 2007 (2007-07-01), pages 32 - 37, XP002593206, ISSN: 0007-1145 *
CANI PATRICE D ET AL: "Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor", DIABETES, vol. 55, no. 5, May 2006 (2006-05-01), pages 1484 - 1490, XP002593207, ISSN: 0012-1797 *
SEIFARTH C ET AL: "Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to .alpha.-glucosidase inhibition (acarbose) in Type 2 diabetic patients", DIABETIC MEDICINE, JOHN WILEY & SONS, LTD, GB, vol. 15, no. 6, 1 June 1998 (1998-06-01), pages 485 - 491, XP002576743, ISSN: 0742-3071 *

Also Published As

Publication number Publication date
EP2197433A2 (en) 2010-06-23
WO2009026389A3 (en) 2009-04-16
WO2009026389A2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
EP2197433A4 (en) Regulating glp-1 and sglt-1 in gastrointestinal cells
GB0708406D0 (en) Improvements in or relating to fuel cells
GB2440434B (en) Fuel cells
GB0718577D0 (en) Fuel cells
GB2435217B (en) Improvements in and relating to neurostimulation
GB2440435B (en) Fuel cells
GB0718349D0 (en) Fuel cells
GB0605878D0 (en) Fuel cells
IL207803A0 (en) Permselective membrane-free direct fuel cell and components thereof
GB0720092D0 (en) Improvements in bus stops and bus shelters
GB0608079D0 (en) Fuel cells
EP2175510A4 (en) Fuel cell
GB2446950B (en) Fuel cell elements
EP2106443A4 (en) Acid ceramidase and cell survival
EP2041820A4 (en) Fuel cell
EP1981111A4 (en) Fuel cell
GB0604802D0 (en) Improvements in and relating to fuel cells
GB2440366B (en) Solar cells
EP2109176A4 (en) Fuel cell
GB0602406D0 (en) Reversible fuel cell
TWI339915B (en) Electrode structure and fuel cell using the same
GB0701405D0 (en) Improvements in and relating to perifheral neurostimulation
GB0601101D0 (en) Solar cell
EP2185685A4 (en) Novel methods and cell lines
EG25157A (en) Filtration cell and filtration device using such cell.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100329

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

R17P Request for examination filed (corrected)

Effective date: 20100315

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7004 20060101ALI20100726BHEP

Ipc: A61K 31/70 20060101ALI20100726BHEP

Ipc: A61P 3/04 20060101ALI20100726BHEP

Ipc: A61P 3/10 20060101ALI20100726BHEP

Ipc: A61K 38/00 20060101ALI20100726BHEP

Ipc: A61K 31/015 20060101AFI20100416BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100806

17Q First examination report despatched

Effective date: 20120224

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120706